Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Sep 3, 2025

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications
08:19

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications

Published on: November 17, 2015

18.0K

Editorial for the Specific Issue: "Lipid-Based Nanocarriers".

Chin-Tin Chen1

  • 1Department of Biochemical Science and Technology, National Taiwan University, No. 1, Sec. 4, Roosevelt Road, Taipei 10617, Taiwan.

Biomedicines
|July 27, 2022
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of Liposomal Formulations for 1,4-bis-L/L Methionine-Conjugated Mitoxantrone-Amino Acid Conjugates to Improve Pharmacokinetics and Therapeutic Efficacy.

Pharmaceutics·2025
Same author

Application of Design of Experiments in the Development of Self-Microemulsifying Drug Delivery Systems.

Pharmaceuticals (Basel, Switzerland)·2023
Same author

Fabrication of Doxorubicin-Loaded Lipid-Based Nanocarriers by Microfluidic Rapid Mixing.

Biomedicines·2022
Same author

Oleic Acid-Based Self Micro-Emulsifying Delivery System for Enhancing Antifungal Activities of Clotrimazole.

Pharmaceutics·2022
Same author

DNA Hypermethylation Involves in the Down-Regulation of Chloride Intracellular Channel 4 (CLIC4) Induced by Photodynamic Therapy.

Biomedicines·2021
Same author

Co-Encapsulation of Chlorin e6 and Chemotherapeutic Drugs in a PEGylated Liposome Enhance the Efficacy of Tumor Treatment: Pharmacokinetics and Therapeutic Efficacy.

Pharmaceutics·2019
Same journal

Precision Proteomic Profiling of Systemic Lupus Erythematosus-Correlating Disease Activity and Complement Levels with Clinical Phenotypes.

Biomedicines·2026
Same journal

The Role of Salivary Microbiota in Pancreatic Cancer: From Screening to Tumor Progression and Treatment Response.

Biomedicines·2026
Same journal

Diagnostic Utility of Surface Electromyography for Identifying Muscles Affected by Myofascial Trigger Points: A Scoping Review.

Biomedicines·2026
Same journal

Performance Assessment of a Locally Semi-Automated NGS-Based Workflow for Homologous Recombination Deficiency Testing in High-Grade Serous Ovarian Carcinoma.

Biomedicines·2026
Same journal

Coupling and Uncoupling Pleiotropy Between Hypertension and Type 2 Diabetes Contribute to Exploring Potential Heterogeneity in Cardiovascular Risk in East Asian Population.

Biomedicines·2026
Same journal

Maternal Response to Therapeutic Plasma Exchange in Early Gestation: A Case Series of Thrombotic Microangiopathies and Neurological Disorders.

Biomedicines·2026
See all related articles

Active pharmaceutical ingredients (APIs) include small molecules and biologics for disease management. Research explores their distinct properties and therapeutic applications in modern medicine.

Area of Science:

  • Pharmaceutical Sciences
  • Drug Discovery and Development

Background:

  • Active pharmaceutical ingredients (APIs) are broadly classified into small molecules and biologics.
  • These two categories represent distinct approaches to therapeutic intervention.

Discussion:

  • Small molecules offer advantages in oral bioavailability and manufacturing scalability.
  • Biologics, such as proteins and antibodies, provide high specificity and potency for targeted therapies.

Key Insights:

  • Understanding the physicochemical and pharmacological differences between small molecules and biologics is crucial for effective drug design.
  • The choice between small molecules and biologics depends on the disease, target, and desired therapeutic outcome.

Outlook:

More Related Videos

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
09:41

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

23.6K
Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes
09:47

Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes

Published on: February 19, 2016

9.8K

Related Experiment Videos

Last Updated: Sep 3, 2025

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications
08:19

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications

Published on: November 17, 2015

18.0K
Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
09:41

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

23.6K
Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes
09:47

Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes

Published on: February 19, 2016

9.8K
  • Future drug development will likely involve continued innovation in both small molecule and biologic platforms.
  • Combination therapies utilizing both modalities may offer synergistic benefits for complex diseases.